Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP | not yet recruiting | Phase 2 | 47 | Yonsei UniversityOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | recruiting | Phase 2 | 315 | Miltenyi Biomedicine GmbHINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT04822337 |
| Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma |
| active not recruiting |
| Phase 1 / Phase 2 |
| 70 |
| Wake Forest University Health SciencesOTHER |
| 1 |
| Jul 13, 2026 |
| clinicaltrials |
| NCT05199311 | Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | suspended | Phase 1 / Phase 2 | 66 | Hackensack Meridian HealthOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06523621 | Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel | active not recruiting | Phase 2 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 96 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | not yet recruiting | Phase 2 | 138 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 13, 2026 | clinicaltrials |
| NCT04419519 | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | active not recruiting | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05303792 | Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 68 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05451771 | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | active not recruiting | Phase 1 / Phase 2 | 53 | Columbia UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05672251 | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06558604 | Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma(GLOASIS) | recruiting | Phase 2 | 100 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT07454187 | To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 40 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695740 | Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 2 | 64 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03568461 | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma(ELARA) | completed | Phase 2 | 98 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 9, 2026 | clinicaltrials |
| NCT06300528 | Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas | active not recruiting | Phase 2 | 1 | University of UtahOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT01880567 | Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03269669 | Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | active not recruiting | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | active not recruiting | Phase 2 / Phase 3 | 422 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06140524 | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma(LINKER-MGUS1) | recruiting | Phase 2 | 116 | Regeneron PharmaceuticalsINDUSTRY | 7 | Jul 8, 2026 | clinicaltrials |
| NCT06723457 | Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma | recruiting | Phase 2 | 34 | Reem KarmaliOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06854159 | Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy | recruiting | Phase 2 | 34 | University of California, DavisOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | not yet recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07657312 | Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma | recruiting | Phase 2 | 35 | Naresh BummaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689058 | CAR-T in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 10 | Dr. Zaineb AkramOTHER_GOV | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07690761 | Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant(Rituximab+ Zan) | enrolling by invitation | Phase 2 | 12 | Bnai Zion Medical CenterOTHER_GOV | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06249191 | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 40 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07687004 | Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification(AL-005) | not yet recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03114865 | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | active not recruiting | Phase 1 / Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03331198 | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | active not recruiting | Phase 1 / Phase 2 | 320 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT04416451 | A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma | active not recruiting | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06083922 | A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) | recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07684950 | Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy | not yet recruiting | Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 244 | Karyopharm Therapeutics IncINDUSTRY | 19 | Jul 2, 2026 | clinicaltrials |
| NCT04775550 | DARA RVD For High Risk SMM(PRISM) | active not recruiting | Phase 2 | 61 | Omar Nadeem, MDOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04850599 | Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 5 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma(EPCORE DLBCL-3) | terminated | Phase 2 | 111 | GenmabINDUSTRY | 12 | Jul 2, 2026 | clinicaltrials |
| NCT06464185 | A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 53 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.(ALACRITY) | recruiting | Phase 1 / Phase 2 | 91 | Alexion Pharmaceuticals, Inc.INDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
| NCT02339922 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04836507 | Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients | recruiting | Phase 1 / Phase 2 | 91 | Curocell Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07557056 | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | not yet recruiting | Phase 2 | 25 | Jennifer WoyachOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06905509 | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | recruiting | Phase 2 | 25 | University of California, DavisOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04587687 | Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma | recruiting | Phase 2 | 23 | University of California, DavisOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06107738 | Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma(IBEX) | recruiting | Phase 2 | 60 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03323151 | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma(PrE0404) | completed | Phase 1 / Phase 2 | 43 | PrECOG, LLC.OTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04257578 | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2026source: clinicaltrials